Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sargramostim · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Sargramostim (Leukine) | DRUG | 6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks |
| Placebo | DRUG | Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks |
Inclusion Criteria: * Stable but active Crohn's disease at the time of screening * Must be able to self-inject or have another person who can help with the injection Exclusion Criteria: * Not have a colostomy or ileostomy * Not be taking prohibited medications as defined in the protocol * Not hav...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Sargramostim is an investigational small molecule being studied for the treatment of Crohn Disease. It is being developed by Sanofi (SNY) and has completed clinical trials in patients with moderate to severe Crohn's disease, as well as in steroid-dependent patients. The drug is not approved and remains in clinical development.
Sargramostim is a small molecule being investigated for Crohn Disease. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here. The drug is being evaluated for its ability to induce response and remission in patients with moderate to severe Crohn's disease.
Sargramostim is being developed by Sanofi, a company traded under the ticker SNY. Sanofi is conducting clinical trials of Sargramostim in patients with Crohn Disease, including a Phase 3 study in moderate to severe disease and a Phase 2 study in steroid-dependent patients.
Sargramostim is in Phase 3 clinical development for Crohn Disease. A Phase 3 trial, NCT00206674, has been completed, along with a Phase 2 trial, NCT00206596. The drug is investigational and has not been approved by regulatory authorities.
Sargramostim has been studied in two completed clinical trials for Crohn Disease. NCT00206674 was a Phase 3 study in 286 patients with moderate to severe Crohn's disease, conducted across multiple countries. NCT00206596 was a Phase 2 study in 127 steroid-dependent patients. Both trials were randomized, double-blind, and placebo-controlled.
Sargramostim is not known to have alternative names in the available information. It is being studied specifically for Crohn Disease by Sanofi. No other names for this drug have been reported in clinical trial records.